Vertaling van "growth and health outcomes " (Frans → Nederlands) :

[2] Kramer, M.S et al. Infant growth and health outcomes associated with 3 compared with 6 mo of exclusive breastfeeding.
[2] Kramer, M.S et al. Infant growth and health outcomes associated with 3 compared with 6 mo of exclusive breastfeeding.

Nutbeam’s framework in Chapter 7 Performance of health promotion) into outcomes very distal to action (like healthh outcomes), intermediate health outcomes (like adopting healthy lifestyle), and more direct
into outcomes very distal to action (like healthh outcomes), intermediate health outcomes (like adopting healthy lifestyle), and more direct

Evolution des résultats des passages des instruments d’outcome « Children Health Locus of Control (CHLC) » et « Multidimensional Health Locus of Control (MHLC) » chez les patients du centre de référence SFC de l’AZ VUB (service de pédiatrie) ou chez leurs parents (portant sur le fonctionnement du patient).
Evolutie van de scores op de outcome-instrumenten Children Health Locus of Control (CHLC) en Multidimensional Health Locus of Control (MHLC) afgenomen bij patiënten van het CVS-referentiecentrum van het AZ VUB (Dienst pediatrie) of bij hun ouders (met betrekking tot het functioneren van de patiënt).

Tableau 73. Evolution des résultats des passages des instruments d’outcome « Children Health Locus of Control (CHLC) » et « Multidimensional Health Locus of Control (MHLC) » 210 chez les patients du centre de référence SFC de l’AZ VUB (service de pédiatrie) ou chez leurs parents (portant sur le fonctionnement du patient).
Tabel 73. Evolutie van de scores op de outcome-instrumenten Children Health Locus of Control (CHLC) en Multidimensional Health Locus of Control (MHLC) 214 afgenomen bij patiënten van het CVS-referentiecentrum van het AZ VUB (Dienst pediatrie) of bij hun ouders (met betrekking tot het functioneren van de patiënt).

Powerpoint slides intervenants - Allocution - Secrétaire d'état Servais Verherstraeten - Allocution - Ministre Laurette Onkelinx - Introduction - Prof. Jean Nève - Présentation " Environment, health, science and progress" - Prof. Andreas Gies - Présentation " Un avis du CSS en matière de Santé Publique et Développement durable" - Prof. Luc Hens - Présentation " Radon à domicile et développement durable" - Prof. François Jamar - Présentation " Alimentation et développement durable" - Prof. Stefaan De Henauw - Présentation " Vieillissement de la population et développement durable" - Prof. Jacques De Mol - Présentation " Molecular detection of noroviruses in ready-to-eat foods and fruit products" - Ambroos Stals (Prix CSS) - Présentation " Immune Monitoring in Type 1 Diabetic Recipients of Defined Beta Cell Graft: Contribution to Assess Clinical Outcome" - Robert Hilbrands (Prix CSS)
Powerpoint slides sprekers - Toespraak - Staatssecretaris Servais Verherstraeten - Toespraak - Minister Laurette Onkelinx - Inleiding - Prof. Jean Nève - Presentatie " Environment, health, science and progress" - Prof. Andreas Gies - Presentatie " Een advies van de HGR inzake Volksgezondheid en Duurzame ontwikkeling" - Prof. Luc Hens - Presentatie " Radon binnenshuis en duurzame ontwikkeling" - Prof. François Jamar - Presentatie " Voeding en duurzame ontwikkeling" - Prof. Stefaan De Henauw - Presentatie " Vergrijzing en duurzame ontwikkeling" - Prof. Jacques De Mol - Présentation " Molecular detection of noroviruses in ready-to-eat foods and fruit products" - Ambroos Stals (HGR Priis) - Présentation " Immune Monitoring in Type 1 Diabetic Recipients of Defined Beta Cell Graft: Contribution to Assess Clinical Outcome" - Robert Hilbrands (HGR Prijs)

The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstlineantihypertensive therapies : a meta-analysis of randomised controlled trials.
The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).JAMA 2002; 288: 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstline antihypertensive therapies : a meta-analysis of randomised controlled trials.

JAMA 2002 ; 288 : 2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.
JAMA 2002 ; 288 :2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.

„They are designed to help practitioners assimilate, evaluate and implement the everincreasing amount of evidence and opinion on best current practice. Clinical guidelines are intended as neither cookbook nor textbook but, where there is evidence of variation in practice which affects patient outcomes and a strong research base providing evidence of effective practice, guidelines can assist doctors and other health care professionals in making decisions about appropriate and effective care for their patients.
variation in practice which affects patient outcomes and a strong research base providing evidence of effective practice, guidelines can assist doctors and other health care professionals in making decisions about appropriate and effective care for their patients.